Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
The efficacy of various drugs used to treat ulcerative colitis, (sulfasalazine, 5-aminosalicylate, hydrocortisone) was investigated in a model of acetic acid-induced colitis in the rat. Subsequently, we tested the ability of antioxidant/5-lipoxygenase inhibitors (gossypol and nordihydroguiaretic acid [NDGA]) and a cyclooxygenase inhibitor (indomethacin) to attenuate the macroscopic colonic damage and/or neutrophil influx (myeloperoxidase activity [MPO]) associated with this model of colitis. Oral pretreatment with either sulfasalazine, gossypol, or NDGA significantly decreased colonic MPO activity induced by acetic acid. Intrarectal administration of such drugs resulted in an even larger reduction of the colonic inflammation, with gossypol being the most potent compound. Oral or intrarectal administration of corticosteroids (dexamethasone, hydrocortisone) also attenuated the parameters of acetic acid induced colitis. In contrast, pretreatment with indomethacin was ineffective, or when administered daily after colitis induction, indomethacin actually increased colonic neutrophil influx significantly. Our data suggest that both the route of drug administration and dosing regimen employed affect the antiinflammatory potency and/or efficacy of compounds on colitis induced by acetic acid in the rat. Drugs which were effective against this colitis may act by scavenging of oxygen derived free radicals.
Fitzpatrick
L R
LR
Gastrointestinal Pharmacology Department, Rorer Central Research, Horsham, PA 19044.
Bostwick
J S
JS
Renzetti
M
M
Pendleton
R G
RG
Decktor
D L
DL
D000085:Acetates; D019342:Acetic Acid; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D006072:Gossypol / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use; D007213:Indomethacin / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D009637:Masoprocol / Q000627:therapeutic use; D019804:Mesalamine; D009504:Neutrophils / Q000201:enzymology; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D012460:Sulfasalazine / Q000627:therapeutic use
D000085:Acetates; D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D012460:Sulfasalazine; D019804:Mesalamine; D009637:Masoprocol; D003907:Dexamethasone; D009195:Peroxidase; D006072:Gossypol; D019342:Acetic Acid; D006854:Hydrocortisone; D007213:Indomethacin